• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Gastroenterology

Genetically engineered lymphocytes inhibit Hepatitis C virus replication in vitro [PreClinical]

byElizabeth CramerandSarah Stapleton
November 20, 2014
in Gastroenterology, Preclinical
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Activated suicide gene modified lymphocytes (SGMLs) inhibit Hepatitis C virus (HCV) replication multiple in vitro models of infection.

2. At low effector:target cell ratios, SGMLs inhibit HCV replication through non-cytotoxic mechanisms and are resistant to calcineurin inhibitors.

Evidence Rating Level: 2 (Good)

Study Rundown: Chronic HCV infections are strongly associated with severe late stage liver disease, including liver cirrhosis and hepatocellular carcinoma, both of which may lead to the need for liver transplantation (LT). Unfortunately, the recurrence of HCV-caused liver disease often follows LT as a result of graft reinfection. Existing treatments for transplant patients are often not ideal as they exhibit poor efficacy, toxicity, and may be prohibitively expensive. Previous work demonstrated the injection of activated graft lymphocytes three days after transplantation reduced HCV viral load in the patients. Unfortunately, in some patients reinfection occurred. It was hypothesized that earlier injection of activated lymphocytes may reduce the chance of reinfection.

In this current proof-of-concept study, healthy, un-related donor lymphocytes were activated ex vivo (or after isolation), and then cultured with target cells recently inoculated with HCV. The activated lymphocytes were also genetically modified to express a vector for a drug-inducible suicide gene to avoid graft-verus-host-disesase (GVHD), which may be induced via the injection of non-self, non-graft lymphocytes.

While in vivo evidence was not demonstrated, in vitro studies demonstrated SGMLs inhibited HCV replication through non-cytotoxic, or non-cell-killing, mechanisms. This anti-viral activity was, at least in part, attributed to soluble factors, and was IFN-Îł-dependent. Graft rejection prevention drugs, cyclosporine A (CsA) and Tacrolimus (FK506), did not inhibit antiviral activity of SGMLs, suggesting SGMLs utility in transplant patients. As expected, SGMLs were depleted with addition of a prodrug targeting the suicide vector, and this depletion eliminated the antiviral effect of SGMLs. While the models of HCV infection used in this work are well accepted, they use a cell line rather than primary hepatocytes as their target cells, which may reduce the heterogeneity of results. Additionally, many of the robust antiviral effects were observed for relatively high effector:target cell ratios, which may be difficult to replicate in vivo.

Click to read the study in Gene Therapy

RELATED REPORTS

Accessible hepatitis C care for people who inject drugs provide significantly higher rates of cure compared to conventional care

Demographic trends associated with increased maternal & neonatal Hepatitis C cases over 10 years

Adenovirus encoding hepatitis C virus vaccine is safe but effectiveness is unclear

Relevant Reading: Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft

In-Depth [in vitro study]: This study used CD3 or CD3/CD28 activated lymphocytes, which were transduced with retroviral vectors expressing the suicide gene iCasp9, to investigate the anti-viral potential of these effector cells when cultured in the presence of virus-transfected target cells. The SGMLs were incubated with two separate models of HSV infection: the HCV replicon or HCVcc model in Huh7.5.1 cells.

At an effector:target cell ratio of 2:1, SGML presence drove an approximate 3-log reduction in HCV replication after three days of co-culture. No strong cytotoxic effects were found, and a transwell experiment that separated the two cell types confirmed the anti-viral effect of the SGMLs was at least partially through soluble factors. Antiviral activity was more potent in the presence of the activating interleukin-2 (IL-2) in the HCVcc model of infection. The soluble antiviral effect was reversed when IFN-Îł blocking antibodies were added to culture media. When SGMLs were introduced on the same day as HCV infection in the HCVcc model of viral replication, inhibition was more pronounced than if the SGMLs were introduced 1-3 days after infection of the target cells. Cryopreserved SGMLs exhibited antiviral activity similar to fresh SGMLs. Calcineurin inhibitors, CsA and FK506, were shown to not affect the antiviral activity of SGMLs at concentrations up to 100 ng/ml (CsA) or 10 ng/ml (FK506). Administration of the prodrug, a chemical inducer of death via the iCasp9 suicide gene, to a cell culture of low target:effector cell ratios, drove SGML depletion and subsequent abrogation of the antiviral activity.

More from this author: Rapamycin inhibits intestinal tumor formation and growth [PreClinical]

Image: PD

©2014 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: hepatitis C
Previous Post

No benefit of adding mitral valve repair to CABG

Next Post

Increased mortality observed in type 1 diabetes

RelatedReports

Large spike in drug use-associated infective endocarditis linked with opioid epidemic
Gastroenterology

Accessible hepatitis C care for people who inject drugs provide significantly higher rates of cure compared to conventional care

March 17, 2022
Social networks play key roles in parental vaccination decisions
Chronic Disease

Demographic trends associated with increased maternal & neonatal Hepatitis C cases over 10 years

November 1, 2021
Compliance-linked incentives increase infant immunizations rates in rural India
Infectious Disease

Adenovirus encoding hepatitis C virus vaccine is safe but effectiveness is unclear

February 10, 2021
Screening insufficient for newborns exposed to hepatitis C virus
Cardiology

Expanding heart transplant in the era of direct-acting antiviral therapy for hepatitis C

December 28, 2019
Next Post
Preterm birth associated with elevated plasma insulin levels

Increased mortality observed in type 1 diabetes

Early tube feeding unable to reduce infections in pancreatitis [PYTHON trial]

Early tube feeding unable to reduce infections in pancreatitis [PYTHON trial]

Classics Series, Landmark Trials in Medicine

HPV triage is optimal management for ASCUS [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.